Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Section 5 of 6

Economic information and modeling report

20 evidence topics · 16 sources

Modeling overview

Summary

  • Barzolvolimab has no published price and no budget impact model; a BLA submission is anticipated in 2027.
  • Comparator prices: remibrutinib $4,521 per 30-day supply (60 tablets) as of January 7, 2026; dupilumab $4,193.03 per 4-week supply as of January 1, 2026; omalizumab approximately $30,000 - $60,000 annually at list price (WAC) per Genentech and approximately $1472.76 per unit at the end of 2025 per the Oregon PDAB review. The Oregon PDAB review lists 2025 WACs per 30-day supply of $5,891 for omalizumab 600 mg every 1 month and $3,993 for dupilumab 300 mg every 2 weeks.
  • Omalizumab biosimilar competition became available in 2026, and a negotiated Medicare Maximum Fair Price for Xolair is scheduled to take effect January 1, 2028.
  • Published cost-effectiveness analyses of comparators report ICERs for omalizumab of £27,469 per QALY gained (NICE TA339, with the patient access scheme), £3183 (UK societal, Novartis-funded), €17 502 per QALY gained (Netherlands societal), and ¥160,411/QALY (China, patient perspective); a US poster reports $3,208,966 per QALY over 10 years for remibrutinib with cetirizine. NICE draft guidance of September 2026 states that remibrutinib should not be used for CSU inadequately controlled by H1-antihistamines in adults. No dupilumab cost-effectiveness analysis in CSU was found.
  • The UK omalizumab model assigns utilities from 0.712 for UAS7 = 28–42 to 0.897 for UAS7 = 0.
  • Celldex states a prevalence of 0.5-1.0% of the total population, or up to approximately 1 to 3 million patients in the United States.

Wholesale acquisition cost per 30-day supply of omalizumab and dupilumab in 2025

ProductQuoted dosage and frequencyQuoted yearQuoted WAC per 30-day supply
Omalizumab (Xolair)“600 mg every 1 month”“2025”“$5,891”
Dupilumab (Dupixent)“300 mg every 2 weeks”“2025”“$3,993”

Dupilumab cost-effectiveness analysis in CSU

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.